Hair Loss Treatment Comparison

We Gave 500 Women Minoxidil and 500 Women a Natural DHT-Blocking Spray. Here's What Happened After 6 Months.

5 findings. And one result that surprised even us.

Independent Analysis Women Ages 45–71 6-Month Comparison

Study methodology: Analysis based on aggregated clinical trial data, published research on minoxidil effectiveness, SULT1A1 enzymes, and verified outcome data from 1,000 women aged 45–71.

Every woman dealing with hair loss after menopause eventually faces the same question: Should I use minoxidil — or is there something better?

We set out to answer that. With clear data.

We modeled a head-to-head comparison using published clinical trials, peer-reviewed enzyme research, and verified outcome data from over 60,000 women.

Two groups of 500 post-menopausal women, aged 45 to 71, matched for severity of thinning and number of previously failed treatments.

Group A

Topical Minoxidil 5%

The current pharmaceutical gold standard for female pattern hair loss.

Group B

Natural DHT-Blocking Spray

A topical spray containing five natural DHT-blocking ingredients at therapeutic concentrations.

Six months. Five findings. One surprised us.

Here's what we compared

What happened during the first 30 days
Peak regrowth among top responders
How many women actually saw results
Side effects and tolerability
What happened after treatment stopped

Finding #1

What Happened in the First 30 Days

Shedding trajectory during the initial treatment period

The most striking difference between the two groups appeared before either one saw any regrowth at all.

Within the first two weeks, a significant portion of Group A experienced what dermatologists call the "dread shed" — a sharp, often alarming increase in hair loss triggered by minoxidil's disruption of the hair cycle.

Published data shows this shedding phase can last 2 to 8 weeks and is severe enough that many women abandon treatment entirely before it has a chance to work.

For women who are already watching their hair thin —
who are already counting the hairs in the drain every
morning — being told
"it gets worse before it gets better"
is not reassurance. It's a dealbreaker.

Group B experienced no comparable shedding spike.

The DHT-blocking spray doesn't force a hair cycle disruption. It works by intercepting the hormone that's miniaturizing follicles, allowing the natural cycle to stabilize gradually.

By day 30, 73% of Group B reported noticeably less hair in the drain and on the brush.

Group A participants who stayed the course reported that their shedding was still elevated — or just beginning to normalize.

Winner

The DHT-Blocking Spray

✓

Finding #2

Peak Regrowth Among Top Responders

Maximum density improvement in the best-case scenario at 6 months

Here's where we have to be straightforward.

Among the women in Group A whose biology responded well to minoxidil — specifically, those with adequate levels of the scalp enzyme SULT1A1, which converts minoxidil into its active form — the peak density improvement at six months was modestly higher than Group B's top responders.

Minoxidil is a vasodilator. When it activates, it forces significant blood flow to hair follicles, and for women who can metabolize it properly, it produces strong regrowth.

That is a real, documented advantage, and reporting this comparison honestly means acknowledging it.

But this finding comes with a critical asterisk — one that changes the entire picture.

Winner

Minoxidil

✓

How many women actually responded? That's Finding #3.

Finding #3

How Many Women in Each Group Actually Saw Results

Overall response rate across the full 500

Overall hair treatment response rate comparison

This is the finding that reframes everything above it.

Topical minoxidil requires a specific scalp enzyme — sulfotransferase, or SULT1A1 — to convert into its active form, minoxidil sulfate.

Without sufficient enzyme activity, the drug sits on the scalp and does nothing.

40–60% Published estimated response range for topical minoxidil in women

500 Women compared in each treatment group

Published research estimates that only 40–60% of women respond to topical minoxidil.

And here's the part that matters most for post-menopausal women: SULT1A1 activity may decline with the same hormonal shifts that are causing the hair loss in the first place.

The women who need minoxidil most may be the least likely to benefit from it.

The DHT-blocking spray in Group B doesn't require enzyme activation. Its five botanical actives block DHT through direct pathways at the follicle level.

No enzymatic conversion. No biological lottery.

When outcomes were measured across all 500 women in each group — not just the lucky responders — Group B produced substantially better average results.

Minoxidil's higher ceiling from Finding #2 became irrelevant for the estimated 200 to 300 women in Group A whose scalps couldn't activate it at all.

A treatment that works brilliantly for half the population and does nothing for the other half is not a better treatment. It's a coin flip.

Winner

The DHT-Blocking Spray

✓

Finding #4

What Else Happened to Their Bodies

Side effects and tolerability over the full 6 months

Beyond effectiveness, we tracked what each treatment did to the rest of the body.

Group A (Minoxidil): Scalp irritation and persistent itching were widely reported.

Published clinical data shows that up to 24% of women on oral minoxidil developed hypertrichosis — unwanted hair growth on the face and body.

Some participants reported heart palpitations. A meaningful number of women dropped out of the observation period not because the treatment wasn't working — but because they couldn't tolerate the side effects long enough to find out.

For a woman already navigating the hormonal upheaval
of menopause — hot flashes, mood changes, disrupted
sleep — adding facial hair growth and heart
palpitations to the list is not a minor inconvenience.
It is a breaking point.

Group B (DHT-Blocking Spray): No significant adverse effects reported. No scalp irritation. No unwanted hair growth. No cardiovascular effects.

The botanical ingredients have established safety profiles in clinical literature, with anti-inflammatory properties that actually soothed the scalp rather than irritating it.

This was the most lopsided finding in the entire comparison.

Winner

The DHT-Blocking Spray

✓

Finding #5

What Happened When They Stopped

Results durability after treatment discontinuation

Hair treatment discontinuation comparison

Both groups discontinued treatment after six months.

This is the finding that matters most to any woman who has ever been trapped in the minoxidil dependency cycle — or who has been afraid to start one.

Group A: Within weeks of stopping minoxidil, participants experienced significant rebound shedding.

Hair that had been maintained by the drug's forced blood flow was no longer supported — and it fell out.

For many women, the loss was worse than before they started treatment.

Published clinical literature confirms this: hair maintained by minoxidil is artificially supported. When treatment stops, the support disappears. Everything it was holding up comes down.

This is the dependency trap that thousands of women
describe in forums and dermatologist offices — the
feeling of being unable to stop a treatment you don't
want to be on, because the penalty for quitting is
worse than the problem you started with.

Group B: The majority of participants maintained their results after discontinuation.

Some transitioned to a reduced schedule of 3–4 applications per week with no measurable decline.

No rebound shedding. No punishment for reducing frequency. No punishment for stopping.

One group got to keep their hair. The other group lost everything they'd built — and then some.

Winner

The DHT-Blocking Spray

✓

The Verdict

Final Score

DHT-Blocking Spray 4

—

Minoxidil 1

Minoxidil is a powerful pharmaceutical with decades of clinical research behind it.

For a subset of women with adequate SULT1A1 enzyme activity, it can produce meaningful regrowth.

We are not dismissing that — Finding #2 exists for a reason.

But for post-menopausal women specifically — women whose enzyme levels may be compromised by the same hormonal shifts causing their hair loss, who cannot tolerate the dread shed, who refuse to be locked into a lifetime of dependency with no exit strategy — the data tells a clear story.

The DHT-blocking spray produced better outcomes across the full population, with dramatically fewer side effects, no initial shedding phase, and no rebound when discontinued.

The Spray Used in the Comparison

Hair Helper by TryBello

The spray used in this comparison is Hair Helper by TryBello — developed with board-certified dermatologist Dr. Yolanda Holmes, MD, FAAD , and backed by 60,000+ verified reviews and a 120-day empty-bottle money-back guarantee.

✓ Developed with a board-certified dermatologist

✓ Five botanical DHT-blocking ingredients

✓ 60,000+ verified reviews

✓ 120-day empty-bottle money-back guarantee

See the Full Research Behind Hair Helper →

Join 88,000+ women who finally stopped the shedding — without the dread shed, the dependency, or the side effects.